New review highlights potential of epicutaneous immunotherapy for food allergies

A new systematic review published in Clinical and Translational Allergy examines the potential of epicutaneous immunotherapy (EPIT) for treating food allergies. The study, conducted by researchers from Tampere University and Imperial College London, analysed data from 11 randomised controlled trials focusing on peanut and cow’s milk allergies. 

EPIT, which involves applying allergen-containing patches to the skin, showed moderate efficacy in desensitising patients. For peanut allergies, the treatment response rate was 51.2% after 12 months of therapy, compared to 22.4% in placebo groups. The therapy demonstrated a favourable safety profile, with localised skin reactions being the most common side effect. 

While the results are encouraging, the researchers note that current evidence is limited to peanut and cow’s milk allergies, with no data on long-term tolerance after stopping treatment. The review highlights the need for further research into EPIT’s long-term effects and its potential for treating other food allergies. 

This analysis provides valuable insights into EPIT as a promising, non-invasive option for food allergy management, particularly for patients who may not tolerate other forms of immunotherapy. 

For the full report visit: Epicutaneous immunotherapy for food allergy: A systematic review and meta-analysis